The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Open accessAbstract
Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194.Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8-11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9-3·9] vs 2·7 months [2·6-2·8]; hazard ratio [HR] 0·79 [95% CI 0·68-0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8-36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5-12·6] vs 7·9 months [6·7-9·1]; HR 0·75 [95% CI 0·60-0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6-15·1] vs 10·3 months [95% CI 8·6-12·2]; HR 0·83 [95% CI 0·70-0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8-11·2] vs 9·1 months [8·4-10·4]; HR 0·94, 95% CI 0·83-1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma.Funding Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with docetaxel, the combination of nintedanib and docetaxel was associated with a higher incidence of gastrointestinal AEs and transient elevation of liver enzymes [102].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Additional unplanned analyses revealed a pronounced impact on OS in patients with fast-progressing disease and patients who were refractory to first-line chemotherapy.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Unfortunately, survival outcomes remain poor and patients often experience substantial toxicity, underscoring a high unmet need. 8 , 9”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Research works printed but not linked: 2
- Hanna, 2013, Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy, Eur J Cancer, 49, 3418
- Reck, 2013, Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy, J Thorac Oncol, 8, O16.01
Cited by
Sorted by citations
Items 901–952 of 952
Li, Y., Zhao, J., Li, R., Yao, X., Dong, X., Chen, W., Chen, J., An, H., Bai, Y., Xu, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5391662
Zhang, B., Ning, F., Liu, X., Li, N., Wang, P., Yao, W., Han, B., Wang, Q., & Zhong, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1625714
Zheng, W., He, Z., Liu, J., Zhang, Y., Gong, C., Wang, B., Shen, J., Guo, L., & Liang, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117333 · Cited by 1
Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohort
Scheffler, M., Tzala, L., Louie, K. S., ten Persigehl, T., Lennartz, S., Öhrling, K., Gehrman, J., Ruge, L., John, F., Rasokat, A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108768
Pérol, M., & Moro‐Sibilot, D. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00073-4
Meng, X.-Y., Yu-mei, C., Sun, N., Zhang, W., Cui, R.-X., Zhang, L., Zheng, C., Sun, Z., Luo, W.-X., & Wang, F. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i12.112548
Neue Substanzen für die Therapie solider Tumoren
Stein, A., & Bokemeyer, C. (2014) · Forum · doi:10.1007/s12312-014-1160-9
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570266
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570275
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570281
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570290
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570284
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570272
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570278
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570287
de Castro, J., Insa, A., Collado‐Borrell, R., Escudero-Vilaplana, V., Martínez‐Martí, A., Fernandez, E., Sullivan, I., Arrabal, N., Carcedo, D., & Manzaneque, A. (2024) · Figshare · doi:10.6084/m9.figshare.26570269
Tang, Z., Zhou, L., Lin, Y., Zhou, M., Li, J., Wu, H., Chen, C., Xie, J., & Lin, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109400
Federico, A. D., Stumpo, S., Danielli, L., Corradi, G., Ricciuti, B., Pecci, F., Alessi, J. V., Wang, X., Giglio, A. D., Bianco, F. L., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100961
Reck, M., Waller, C. F., Sadjadian, P., Kambartel, K.-O., Grohé, C., Sendler, A., Reinmuth, N., Rittmeyer, A., Marin-Galiano, M., Wirtz, R., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109318
Self-citationLi, Y., Zhao, J., Chen, J., Zhou, C., Yan, Y., Chen, W., Xu, Y., & Li, Y. (2026) · iScience · doi:10.1016/j.isci.2026.114951
Cappuzzo, F., Zhang, L., Dunton, K., Dennis, N., Nouveau, P. L., Nevière, A., & Gauthier, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1708245
Zhou, Q., Gao, B., Hu, J., Zhao, J., Wang, M., He, K., Zhang, W., Liu, C., Fang, J., Li, X. Y., et al. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-000890
Suzuki, R., Watanabe, S., Shono, K., MASUDA, T., Yanai, K., Yamazaki, R., Ando, Y., Wakabayashi, T., Tanaka, S., Sekiya, T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04350-x
Haj-Shomaly, J., Castillo‐Kauil, A., Bloom, C., Hodivala‐Dilke, K., & D’Amico, G. (2026) · Journal of Cell Science · doi:10.1242/jcs.264224
Nardin, S., Vezzoli, F., Cognolato, G., Mollace, R., Pollone, B. R., Biello, F., Cao, D., Tagliamento, M., Sarocchi, M., Pagnesi, M., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1790897
Pierret, T., Descourt, R., Corre, R., Tomasini, P., & Decroisette, C. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.02.003
Chi, C., Li, L., & Xu, C. (2026) · OncoTargets and Therapy · doi:10.2147/ott.s578933
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Garassino, M. C., Cousin, S., Besse, B., Sacher, A., Orlov, S., Schenker, M., Felip, E., Gladkov, O. A., Messina, C. H., Majumdar, A., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.04.003
Self-citationGu, C., He, J., Fan, J., Wang, C., Zhou, W., Xu, Y., 邓婷芬, Wang, P., & Wang, P. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178895
Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance
Ashrai, P., Zishan, S., & Kotnis, A. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45717-3.00016-7
Pedder, H., Manzano, C. L., Claxton, L., Whiting, P. F., Beggs, L., Sadek, A., Lokuge, K., Tomlinson, E., Cooper, C., James, R., et al. (2025) · Health Technology Assessment · doi:10.3310/gjnw3422
TROP-2 as a therapeutic target in NSCLC: The promise of Sacituzumab tirumotecan
Sofianidi, A. A., Papavassiliou, K. A., & Zagouri, F. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105482
Zhang, Q., Feng, Q., Lei, S., Yang, W. Z., Zhang, W., & Liu, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1836198
Is Telisotuzumab Vedotin Effective? A Mechanism-Informed Evidence ReviewPreprint
Michaelis, M., & Williamson, J. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7242920
Zong, Y., Wang, L., Li, X., Cheng, X., Li, J., Sun, Z., Tang, H., Zhou, C., Cao, Y., Luo, H., et al. (2026) · European Radiology · doi:10.1007/s00330-026-12764-5
Mechanotransduction via YAP/TAZ shapes the tumour immune microenvironment
Li, Z., Jin, N., Yang, K., Mei, J., Zeng, T., Jiang, F., Zhao, X., Zhang, Y., Lu, M., Cheng, W., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105569
Fadel, O. E., Alysandratos, K., Hawkins, F. J., & Shankar, D. A. (2026) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2026.102497
Li, M., Wu, Z., Zheng, X., Zhu, Y., Wu, Y., He, J., Wu, X., Xu, J., & Qin, Y. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01412-1
Intratracheal instillation of Janus biomimetic nanomotors for lung adenocarcinoma therapy
Zhang, Y., Yilun, W., Yibo, S., Lu, Y., Xia, J., Xueying, Q., Zhang, L., Lulu, G., Yuan, L., Wang, Q., et al. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.117009
Therapeutic applications of metal complexes in lung cancer treatment
Feng, J., Li, H., Cai, C., Mo, L., Zhu, Y., Lei, Z.-N., Lai, Y., Zhou, B., Pan, Y., Zeng, L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119320
Hong, Y., Laughlin, A. M. M., Pan, Y., Hietala, S. F., Peigné, S., Chargualaf, M., Tang, Z., Zhou, D., Tajima, N., Abutarif, M. A., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70477
Foundations of Cancer and Parenteral Oncology Therapies
Moreira, F. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch001
Lin, H., Wang, K., Chen, H., Tan, G., Zhu, J., Liu, H., & Yang, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105659
Westerink, L., Postma, M. J., van Boven, J. F. M., & Boersma, C. (2026) · The European Journal of Health Economics · doi:10.1007/s10198-026-01954-z
BindingDB Entry 50045598: Nintedanib: from discovery to the clinic.
BindingDB (2016) · UC San Diego · doi:10.7270/q2hh6msg
Metadata
- Authors
- Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.-N., Barrueco, J., Gaschler-Markefski, B., & Novello, S.
- Affiliations
- German Center for Lung Research (DE)
- Boehringer Ingelheim (Germany) (DE)
- Herlev Hospital (DK)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Meir Medical Center (IL)
- Dnipro State Medical University (UA)
- Shanghai Jiao Tong University (CN)
- Boehringer Ingelheim (United States) (US)
- University of Turin (IT)
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 15
- Issue
- 2
- Pages
- 143-155
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2170030318
- Cited by
- 951
- References
- 36
- Citations by year
- 2026: 35 · 2025: 41 · 2024: 64 · 2023: 67 · 2022: 74 · 2021: 67 · 2020: 72 · 2019: 83 · 2018: 81 · 2017: 117 · 2016: 103 · 2015: 102 · 2014: 45
- FWCI
- 98.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, docetaxel, nintedanib, second-line therapy, progression-free survival, overall survival, tyrosine kinase inhibitors, EGFR inhibitors, bevacizumab, brain metastases, adenocarcinoma, targeted therapy, combination chemotherapy, drug safety and tolerability
- MeSH terms
- Docetaxel, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Europe, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Risk Factors, South Africa, Time Factors, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
